LAMEA Minimal Residual Disease Testing Market Size, 2028

LAMEA Minimal Residual Disease Testing Market Size, Share & Industry Trends Analysis Report By Application (Hematological Malignancies, Leukemia, Lymphoma, Solid Tumors and Others), By End User, By Technology, By Country and Growth Forecast, 2022 - 2028

Published Date: January-2023 | Number of Pages: 94 | Format: PDF | Report ID: KBV-21933

Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support


COVID-19

Get in-depth analysis of the COVID-19 impact on the LAMEA Minimal Residual Disease Testing Market

Market Report Description

The Latin America, Middle East and Africa Minimal Residual Disease Testing Market would witness market growth of 19.4% CAGR during the forecast period (2022-2028).

After primary cancer therapy, potential MRD diagnoses are essential for making intelligent individual and long-term clinical decisions. Additionally, MRD diagnosis effectiveness is critical for healthcare insurance firms to successfully provide financial aid to cancer survivors around the world.

Finally, the successful implementation of a particular cancer treatment regimen depends on the measurement of therapeutic results. As a result, MRD testing is being employed more frequently as the final stage of end-point analysis in several clinical trial studies for oncology-based research. It also efficiently captures variances in outcomes resulting from unique genetic traits.

In the coming years, major participants in the minimal residual disease testing market would have the opportunity for expansion in developing economies. This can be linked to the growing elderly population, the rising frequency of hematologic cancers, the rising cost of healthcare per person, and the development of the healthcare system.

In this region, leukemia is one of the leading causes of cancer mortality among children. As a result, it is considered the main health challenge. The restricted access to healthcare, socioeconomic disparities, and the significant lack of economic resources in the region lowers the survival rates that are conventionally witnessed in high-income nations. The delay in diagnosis, lack of supportive care, dearth of pediatric oncologists and nurses, and frequent treatment abandonment also result in increasing children mortality proportions in the region.

The Brazil market dominated the LAMEA Minimal Residual Disease Testing Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $50.3 million by 2028.The Argentina market is experiencing a CAGR of 20% during (2022 - 2028). Additionally, The UAE market would display a CAGR of 19.1% during (2022 - 2028).

Based on Application, the market is segmented into Hematological Malignancies, Leukemia, Lymphoma, Solid Tumors and Others. Based on End User, the market is segmented into Hospitals & Specialty Clinics, Diagnostic Laboratories, Academic & Research Institutes and Others. Based on Technology, the market is segmented into Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Flow Cytometry and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

Free Valuable Insights: The Global Minimal Residual Disease Testing Market is Predict to reach $2.7 Billion by 2028, at a CAGR of 14.2%

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bio-Rad Laboratories, Inc., Guardant Health, Inc., Invitae Corporation (ArcherDX, Inc.), Bio-Techne Corporation, F. Hoffmann-La Roche Ltd., ICON plc (MolecularMD Corporation), Natera, Inc., Sysmex Corporation, Laboratory Corporation of America Holdings, and Invivoscribe, Inc.

Scope of the Study

Market Segments Covered in the Report:

By Application

  • Hematological Malignancies
  • Leukemia
  • Lymphoma
  • Solid Tumors
  • Others

By End User

  • Hospitals & Specialty Clinics
  • Diagnostic Laboratories
  • Academic & Research Institutes
  • Others

By Technology

  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Flow Cytometry
  • Others

By Country

  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

  • Bio-Rad Laboratories, Inc.
  • Guardant Health, Inc.
  • Invitae Corporation (ArcherDX, Inc.)
  • Bio-Techne Corporation
  • F.Hoffmann-La Roche Ltd.
  • ICON plc (MolecularMD Corporation)
  • Natera, Inc.
  • Sysmex Corporation
  • Laboratory Corporation of America Holdings
  • Invivoscribe, Inc.

Unique Offerings from KBV Research

  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Related Reports:

Global Minimal Residual Disease Testing Market Report 2022-2028

North America Minimal Residual Disease Testing Market Report 2022-2028

Asia Pacific Minimal Residual Disease Testing Market Report 2022-2028

Europe Minimal Residual Disease Testing Market Report 2022-2028

Purchase Report

 1500
 1800
 2520

Special Pricing & Discounts

  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities